Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell Published: 2025 Correction to: Nature Communications 10.1038/s41467-025-59744-9, published online 16 May 2025 In the version of this article initially published, the greater than/equal to symbols and less than symbols in the Table 1 “PD-L1 expression (SP263)” entries were inverted and are now corrected to read “Positive (TPS ≥ 1)” and “Negative (TPS < 1).” In Fig. 2c, key colors in the left-hand grid were incorrect and are now updated. In the second paragraph of the Results “Progression-free survival and overall survival” section, in the sentence now reading “Out of the 41 patients, four died during a median follow-up of 37.3 months (95% CI 32.5–42.1), and 6 were deceased by the DCO,” the text has been amended to include six deaths occurring by the later cutoff date. In the Methods “Statistical analysis” section, fourth paragraph, in the text now reading “PROs DCO and analysis were performed three months after the efficacy and safety DCO, for all treated patients who completed the baseline assessment and at least one PRO questionnaire post-baseline. These DCO discrepancies make the efficacy and QoL datasets differ in analysis date and thus evaluable population,” text has been added to clarify a later PRO analysis date and resulting difference in evaluable populations. The table, figure and text have been updated in the HTML and PDF versions of the article.